Effects of Residual Renal Function on Left Ventricle and Analysis of Related Factors in Patients with Hemodialysis

REFERENCES

• Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT. Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. The NECOSAD Study Group. Am J Kidney Dis. 1997;29:584–592.
   PubMed Web of Science ®Google Scholar
• Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT. Predictors of poor outcome in chronic dialysis patients: The Netherlands Cooperative Study on the Adequacy of Dialysis. The NECOSAD Study Group. Am J Kidney Dis. 2000;35:69–79.
   PubMed Web of Science ®Google Scholar
• Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001;38:85–90.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995;5:2024–2031.
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–1566.
   PubMed Web of Science ®Google Scholar
• Parfrey PS, Harnett JD, Griffiths SM, . The clinical course of left ventricular hypertrophy in dialysis patients. Nephron. 1990;55:114–120.
   PubMed Web of Science ®Google Scholar
• Gunal AI, Kirciman E, Guler M, Yavuzkir M, Celiker H. Should the preservation of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients? Ren Fail. 2004;26:405–409.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Carini G, Circo A, . Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001;38:1829–1835.
   PubMed Web of Science ®Google Scholar
• Bachmann J, Tepel M, Raidt H, . Hyperhomocysteinemia and the risk of vascular disease in hemodialysis patients. J Am Soc Nephrol. 1995;6:121–125.
   PubMed Web of Science ®Google Scholar
• Moustapha A, Naso A, Nahlawi M, . Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998;97:138–141.
   PubMed Web of Science ®Google Scholar
• Robinson K, Gupta A, Dennis V, . Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996;94:2743–2748.
   PubMedGoogle Scholar
• Rossi GP, Seccia TM, Pessina AC. Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link? Clin Chem Lab Med. 2007;45:1645–1651.
   PubMedGoogle Scholar
• Cesari M, Zanchetta M, Burlina A, . Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives. Arterioscler Thromb Vasc Biol. 2005;25:115–121.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Benedetto FA, . Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12:1508–1515.
   PubMed Web of Science ®Google Scholar
• Naganuma T, Sugimura K, Wada S, . The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol. 2002;22:437–444.
   PubMedGoogle Scholar
• Mallamaci F, Zoccali C, Tripepi G, . Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001;59:1559–1566.
   PubMed Web of Science ®Google Scholar
• Sanjuan R, Oliva SM, Blasco ML, . Plasma brain natriuretic peptide levels in cardiac function assessment in chronic dialysis patients. Cardiorenal Med. 2011;1:147–155.
   PubMedGoogle Scholar
• Schiller NB, Shah PM, Crawford M, . Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367.
   PubMed Web of Science ®Google Scholar
• Carofei O, Galeotti P, Satriani M, Pedulla F, Taratufolo A. Clinical impact of residual function in hemodialysis. EDTNA ERCA J 1997; 23:54–56.
   PubMedGoogle Scholar
• Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K. Residual renal function improves outcome in incremental hemodialysis despite reduced dialysis dose. Nephrol Dial Transplant. 2009;24:2502–2510.
   PubMed Web of Science ®Google Scholar
• Suda T, Hiroshige K, Ohta T, . The contribution of residual renal function to overall nutritional status in chronic hemodialysis patients. Nephrol Dial Transplant. 2000;15:396–401.
   PubMedGoogle Scholar
• Moist LM, Port FK, Orzol SM, . Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 2000;11:556–564.
   PubMed Web of Science ®Google Scholar
• Van Olden RW, van Acker BA, Koomen GC, Krediet RT, Arisz L. Time course of inulin and creatinine clearance in the interval between two hemodialysis treatments. Nephrol Dial Transplant. 1995;10:2274–2280.
   PubMedGoogle Scholar
• Foley RN, Parfrey PS, Harnett JD, . Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–192.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 1998;54:1720–1725.
   PubMed Web of Science ®Google Scholar
• Wang AY, Wang M, Lam CW, Chan IH, Zhang Y, Sanderson JE. Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease. Hypertension. 2008;52:107–114.
   PubMed Web of Science ®Google Scholar
• Araujo S, Lemes HP, Cunha DA, Queiroz VS, Nascimento DD, Ferreira Filho SR. Cardiac morphology and function in patients with and without residual diuresis on hemodialysis. J Bras Nefrol. 2011;33:74–81.
   PubMedGoogle Scholar
• De Koning L, Hu FB. Homocysteine lowering in end-stage renal disease: is there any cardiovascular benefit? Circulation. 2010;121:1379–1381.
   PubMedGoogle Scholar
• Anan F, Masaki T, Umeno Y, . Correlations between homocysteine levels and atherosclerosis in Japanese type 2 diabetic patients. Metabolism. 2007;56:1390–1395.
   PubMedGoogle Scholar
• Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008;4:672–681.
   PubMedGoogle Scholar
• Anan F, Takahashi N, Shimomura T, . Hyperhomocysteinemia is a significant risk factor for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis. Metabolism. 2006;55:656–661.
   PubMedGoogle Scholar
• Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium- dependent vasodilation in humans. Circulation. 1997;95: 1119–1121.
   PubMed Web of Science ®Google Scholar
• Wang H, Yoshizumi M, Lai K, . Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem. 1997;272: 25380–25385.
   PubMed Web of Science ®Google Scholar
• Hörl WH. Natriuretic peptides in acute and chronic kidney disease and during renal replacement therapy. J Investig Med. 2005;53:366–370.
   PubMedGoogle Scholar
• Collado S, Coll E, Deulofeu R, . Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors. Nefrologia. 2010;30:342–348.
   PubMedGoogle Scholar
• Herrmann M, Taban-Shoma O, Hübner U, . Hyperhomocysteinemia and myocardial expression of brain natriuretic peptide in rats. Clin Chem. 2007;53:773–780.
   PubMedGoogle Scholar